cefotiam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 548 61622-34-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefotiam
  • cefotiam hydrochloride
  • cefotiam HCl
One of the CEPHALOSPORINS that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.
  • Molecular weight: 525.62
  • Formula: C18H23N9O4S3
  • CLOGP: -3.37
  • LIPINSKI: 2
  • HAC: 13
  • HDO: 3
  • TPSA: 172.46
  • ALOGS: -2.61
  • ROTB: 10
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 g O
4 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 80 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 190.25 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.26 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.50 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.84 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.575 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.993 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.404 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.265 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 80.470 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 51.900 % High 1
herg hERG pIC50 4.513 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.466 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.963 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 62.720 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CA,PIK3CB,PIK3CD,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TTK 37
kinase-selectivity-class AXL,EIF2AK3,GRK2,MAP2K6,MAPK7,STK33,TEK 7
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.102 High 1
mh-clint Mouse hepatocyte intrinsic clearance 2.075 High 1
mppb Mouse plasma protein binding (% unbound) 82.320 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.799 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 59.610 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.570 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 88.190 % High 1
rppb Rat plasma protein binding (% unbound) 65.430 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 959.401 uM High 1

Approvals:

DateAgencyCompanyOrphan
None FDA TAKEDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic epidermal necrolysis 67.42 59.22 15 165 32513 90595754

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic epidermal necrolysis 56.11 43.07 17 447 56710 110532125

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DC07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Second-generation cephalosporins
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:36047 antibacterial drug

Related Drugs by ATC class:

J01DC Second-generation cephalosporins 13 drugs
cefaclorcefamandolecefbuperazonecefmetazolecefminoxcefonicidceforanidecefotetancefoxitincefprozilcefuroximeflomoxef show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.63 acidic
pKa2 7.38 Basic
pKa3 4.64 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Matrix metalloproteinase-9 Enzyme IC50 4.46 WOMBAT-PK
Vasoactive intestinal polypeptide receptor 1 GPCR IC50 4.47 WOMBAT-PK
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK

External reference:

IDSource
N0000166878 NUI
D01819 KEGG_DRUG
2188 RXNORM
C0007556 UMLSCUI
CHEBI:355510 CHEBI
CHEMBL1296 ChEMBL_ID
CHEMBL4303232 ChEMBL_ID
D015310 MESH_DESCRIPTOR_UI
DB00229 DRUGBANK_ID
12254 IUPHAR_LIGAND_ID
4565 INN_ID
66309-69-1 SECONDARY_CAS_RN
91W6Z2N718 UNII
43708 PUBCHEM_CID
421700007 SNOMEDCT_US
422345006 SNOMEDCT_US
005393 NDDF
005394 NDDF

Pharmaceutical products:

None